392P Updated data of biodistribution and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas

Abstract

In a report on 15 pts included in TG6002.02 dose-escalation trial (ESMO 2021, Abstract #3550), we showed that TG6002, an oncolytic vaccinia virus deleted in 2 genes to selectively replicate in tumor cells and encoding FCU1, an enzyme converting 5-FC into 5-FU, was biodistributed and replicated in tumor tissue after IV administration and expressed a functional payload. Herein, we report the data with 15 additional pts treated with either higher doses of TG6002 or a more intensive schedule of administration.